Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
2.535
-0.295 (-10.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
December 13, 2023
Pre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching!
Via
InvestorPlace
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
December 12, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Crude Oil Down 4%; Aditxt Shares Spike Higher
↗
December 12, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Tuesday. The Dow traded up 0.32% to 36,520.57 while the NASDAQ rose 0.46% to 14,498.23. The S&P...
Via
Benzinga
Topics
Stocks
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
December 12, 2023
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
December 12, 2023
Via
Benzinga
Dow Jumps Over 100 Points; Oracle Posts Mixed Q2 Results
↗
December 12, 2023
U.S. stocks turned higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.35% to 36,533.63 while the NASDAQ rose 0.16% to 14,455.15 The S&P...
Via
Benzinga
Topics
Stocks
Why Is Aditxt (ADTX) Stock Up 58% Today?
↗
December 12, 2023
Aditxt stock is up on Tuesday as investors in ADTX shares react to the company announcing plans to acquire Evofem Biosciences.
Via
InvestorPlace
EGLE Stock Pops as Star Bulk Buys Eagle Bulk for $500 Million
↗
December 12, 2023
Eagle Bulk Shipping stock is climbing higher on Tuesday after EGLE investors learned of a merger agreement with Star Bulk Carriers.
Via
InvestorPlace
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?
↗
December 12, 2023
C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck.
Via
InvestorPlace
Expert Ratings for C4 Therapeutics
↗
November 03, 2023
Via
Benzinga
US Stocks Edge Lower; Inflation Rate Slows to 3.1% In November
↗
December 12, 2023
U.S. stocks traded slightly lower this morning, following the release of inflation data on Tuesday. Following the market opening Tuesday, the Dow traded down 0.04% to 36,389.01 while the NASDAQ fell...
Via
Benzinga
Topics
Economy
Stocks
Why Is Cancer-Focused C4 Therapeutics Stock Soaring Today?
↗
December 12, 2023
C4 Therapeutics Inc (NASDAQ: CCCC) has entered into an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop degrader-antibody conjugates (DACs), an emerging modality...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
December 12, 2023
Via
Benzinga
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)
December 12, 2023
Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
November 28, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
November 20, 2023
Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 01, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
October 23, 2023
Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
October 23, 2023
Via
Benzinga
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple
October 11, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Chief Financial Officer Succession
September 05, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
July 06, 2023
Via
Benzinga
Nasdaq Edges Lower Following Fed Minutes; C4 Therapeutics Shares Jump
↗
July 05, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones dropping around 100 points on Wednesday. The Dow traded down 0.30% to 34,316.70 while the NASDAQ fell 0.04% to 13,811.43....
Via
Benzinga
Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher
↗
July 05, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 50 points on Wednesday. The Dow traded down 0.17% to 34,361.31 while the NASDAQ fell 0.14% to 13,797.72. The S&P 500,...
Via
Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
July 05, 2023
Via
Investor Brand Network
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May
↗
July 05, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell...
Via
Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
July 05, 2023
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
July 05, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.